13FJ

TGFB1 IN COMPLEX WITH NIS793 FAB

Summary for 13FJ

• Entry DOI: 10.2210/pdb13fj/pdb
• Descriptor: Transforming growth factor beta-1, NIS793 Fab heavy chain, NIS793 Fab light chain, ... (5 entities in total)
• Functional Keywords: tgfb1, nis793, cytokine
• Biological source: Homo sapiens (human); More
• Total number of polymer chains: 6
• Total formula weight: 118993.46

Authors

Zhou, Z.,Zhu, X.,Clark, K. (deposition date: 2026-05-04, release date: 2026-06-17, Last modification date: 2026-07-29)

Primary citation

Pelletier, M.,Yang, J.,Joshi, M.,Grauel, A.,Abecunas, C.,Altzerinakou, M.A.,Zhou, Z.,Zhu, X.,Clark, K.,Li, L.,Bai, L.Y.,Milella, M.,Mercade, T.M.,Tai, W.M.D.,Bockorny, B.,Grell, P.,Sivakumar, S.,Wong, M.K.,Chee, C.E.,Aparicio, T.,Prager, G.,Bostel, G.,Schiessl, B.,Maacke, H.,Dranoff, G.,Shaw, A.,Fabre, C.,Mataraza, J.,Malek, S.,Cremasco, V.
Biomarker analysis from patients with metastatic PDAC treated with TGF beta antibody, NIS793, plus abraxane+gemcitabine vs. abraxane+gemcitabine alone in a phase II, open label, randomized study.
Clin.Cancer Res., 2026

PubMed Abstract: Transforming Growth Factor Beta (TGFβ) plays a dual role in cancer, acting as a tumor suppressor early in disease but promoting progression and immune evasion when dysregulated. In pancreatic ductal adenocarcinoma (PDAC), TGFβ-driven desmoplasia fosters chemoresistance and immunosuppression, limiting therapeutic efficacy. NIS793, a fully human monoclonal antibody targeting TGFβ, demonstrated anti-fibrotic and immunomodulatory activity in preclinical models and early-phase trials.

PubMed: 42347868
DOI: 10.1158/1078-0432.CCR-26-0805

Experimental method

X-RAY DIFFRACTION (2.75 Å)